ArticleFrontiers in endocrinology2020
P2Y
Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Dietary Nucleotides as Potential Modulators of Inflammatory and Metabolic Pathways with Implications for Insulin Resistance.International journal of molecular sciences · 2026Review
- Gene expression alterations of purinergic signaling components in obesity-associated intestinal low-grade inflammation in type 2 diabetes.Purinergic signalling · 2024Article
- The P2YThe Journal of biological chemistry · 2024Article
- Article
- Therapeutic potential for P2YPurinergic signalling · 2023Review
- Purinergic receptor: a crucial regulator of adipose tissue functions.Purinergic signalling · 2023Review
- Sex-specific effect of P2YFrontiers in endocrinology · 2023Article
- Role of purinergic signalling in obesity-associated end-organ damage: focus on the effects of natural plant extracts.Frontiers in endocrinology · 2023Review
- Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets.Current opinion in pharmacology · 2022Review
- Absence of P2YFrontiers in endocrinology · 2022Article
- A nine-hub-gene signature of metabolic syndrome identified using machine learning algorithms and integrated bioinformatics.Bioengineered · 2021Article
- Recommended tool compounds and drugs for blocking P2X and P2Y receptors.Purinergic signalling · 2021Review
- The Adenosine Pathway and Human Immunodeficiency Virus-Associated Inflammation.Open forum infectious diseases · 2021Review
- Resveratrol and Quercetin as Regulators of Inflammatory and Purinergic Receptors to Attenuate Liver Damage Associated to Metabolic Syndrome.International journal of molecular sciences · 2021Article
- High extracellular ATP levels released through pannexin-1 channels mediate inflammation and insulin resistance in skeletal muscle fibres of diet-induced obese mice.Diabetologia · 2021Article
- P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.International journal of molecular sciences · 2021Article
- Purinergic signaling in diabetes and metabolism.Biochemical pharmacology · 2021Review
- High-Fat Diet-Induced Renal Proximal Tubular Inflammatory Injury: Emerging Risk Factor of Chronic Kidney Disease.Frontiers in physiology · 2021Review
- Metabolic Changes Induced by Purinergic Signaling: Role in Food Intake.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.